Friday, 28 Feb 2020

You are here

Dr. Arthur Kavanaugh: Biosimilars and Drug Switching (Abstract 19L)

Dr. Arthur Kavanaugh discusses abstract 19L: Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway, as presented at the 2016 ACR/ARHP Annual Meeting (http://acrabstracts.org/abstract/biosimilar-infliximab-ct-p13-is-not-inferior-to-originator-infliximab-results-from-a-52-week-randomized-switch-trial-in-norway/).

Add new comment

Want to talk about this video? Comment here to lead the discussion.
MORE VIDEOS

Dr. Nayef Al Ghanim: RheumNow and RWCS

14 Nov 2016

The RheumNow Week in Review – FDA...

27 Apr 2018

QD Clinic - The Power of Patient Choice

15 Mar 2019

Dr. Cassandra Calabrese: Checkpoint...

07 Nov 2017

The RheumNow Week in Review – 2...

02 Dec 2016

Dr. Marty Bergman: Addressing Physician...

18 Feb 2019

Dr. Ai Lyn Tan - Doctors Should Be on...

19 Jun 2017

RWCS 2017: Neurobrucellosis, A Case of...

03 Apr 2017

RheumNow Podcast – Eat Your Veggies (4...

19 Apr 2019

The RheumNow Week in Review - 6 October...

06 Oct 2017

Tattoo Granulomatous Reaction with...

13 Feb 2020

Dr. Bill Shergy: Reproductive Health...

24 Oct 2018